Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2022-02-11 3:12 pm Sale | 13G | Aclaris Therapeutics, Inc. ACRS | Foresite Capital Fund III L.P. | 4,657,277 7.6% | -1,954,904 (-29.57%) | View |
| 2021-02-16 10:41 am Sale | 13G | CymaBay Therapeutics, Inc. CBAY | Foresite Capital Fund III L.P. | 3,428,898 5% | -390,828 (-10.23%) | View |
| 2021-02-11 2:56 pm Purchase | 13G | Aclaris Therapeutics, Inc. ACRS | Foresite Capital Fund III L.P. | 6,612,181 13.7% | 4,381,241 (+196.39%) | View |
| 2020-10-26 7:47 pm Purchase | 13G | Aclaris Therapeutics, Inc. ACRS | Foresite Capital Fund III L.P. | 2,230,940 5.2% | 2,230,940 (New Position) | View |
| 2020-02-13 9:17 pm Sale | 13G | CymaBay Therapeutics, Inc. CBAY | Foresite Capital Fund III L.P. | 3,819,726 5.6% | -398,633 (-9.45%) | View |
| 2020-02-13 9:16 pm Sale | 13G | Replimune Group, Inc. REPL | Foresite Capital Fund III L.P. | 313,922 0.8% | -1,695,390 (-84.38%) | View |
| 2019-02-13 1:00 pm Purchase | 13G | Achaogen Inc. AKAO | Foresite Capital Fund III L.P. | 2,864,664 6.2% | 489,664 (+20.62%) | View |
| 2019-02-13 1:00 pm Purchase | 13G | CymaBay Therapeutics, Inc. CBAY | Foresite Capital Fund III L.P. | 4,218,359 7.1% | 1,363,857 (+47.78%) | View |
| 2019-02-13 1:00 pm Sale | 13G | Arcus Biosciences, Inc. RCUS | Foresite Capital Fund III L.P. | 2,028,876 4.6% | -2,066,585 (-50.46%) | View |
| 2019-01-23 5:28 pm Purchase | 13G | Replimune Group, Inc. REPL | Foresite Capital Fund III L.P. | 2,009,312 6.4% | 2,009,312 (New Position) | View |
| 2018-03-23 2:14 pm Purchase | 13G | Arcus Biosciences, Inc. RCUS | Foresite Capital Fund III L.P. | 4,095,461 9.6% | 4,095,461 (New Position) | View |